Form 4: Alkermes EVP Gaffin Exercises RSUs, Sells Shares

Alkermes plc. Executive Vice President and Chief Legal Officer, David Joseph Gaffin, exercised restricted stock units and subsequently sold a portion of the resulting ordinary shares for tax purposes.

Summary

• David Joseph Gaffin, EVP, CLO of Alkermes, Inc., engaged in transactions involving Alkermes plc. ordinary shares.
• On February 23, 2026, Gaffin acquired 7,689 ordinary shares through the exercise of restricted stock units.
• Concurrently, Gaffin disposed of 3,414 ordinary shares at a price of $32.19 per share, likely to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Gaffin directly beneficially owns 235,877 ordinary shares and 7,690 restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical of executive compensation vesting and tax-related share dispositions, offering no strong positive or negative signal regarding the company's operational performance or future prospects.

Positives

• Executive David Joseph Gaffin exercised 7,689 restricted stock units, indicating the vesting of previously granted equity compensation.

Negatives

• David Joseph Gaffin disposed of 3,414 ordinary shares, reducing his direct beneficial ownership of the company's stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions like this Form 4 filing are common occurrences in the biotechnology and pharmaceutical industry, often reflecting the vesting schedules of executive compensation plans rather than a direct signal of management's sentiment on future stock performance. The sale of shares to cover tax obligations upon RSU vesting is a standard practice.

Comparison to Industry Standards

• The transaction aligns with typical executive compensation practices observed across the S&P 500, where restricted stock units vest over several years, and a portion of the shares are often sold to cover statutory tax withholding obligations upon vesting. This is a routine event and not indicative of a unique company-specific trend compared to peers like Biogen or Vertex Pharmaceuticals, which also utilize similar equity compensation structures.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine executive compensation event.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of restricted stock units and a subsequent sale of shares to cover tax obligations. Such transactions are common and generally do not provide new material information that would warrant a change in investment recommendation. The event is neutral in its implications for the company's fundamentals or future stock performance.

Keywords

Alkermes, ALKS, Form 4, insider trading, executive compensation, stock transaction, RSU, restricted stock unit, share sale